Table 1.
Patients’ characteristics
| |
Control |
Tomotherapy |
|---|---|---|
| n = 32 | n = 37 | |
| Age |
|
|
| <50 |
10 |
15 |
| > = 50 |
22 |
22 |
| Left breast tumor |
16 |
24 |
| Medial location |
12 |
8 |
| Tumor size |
|
|
| T1 (<= 20 mm) |
21 |
26 |
| T2 (21–50 mm) |
11 |
11 |
| Nodal status, Lymph node ratio |
|
|
| pN0 |
21 |
24 |
| pN1, LNR 0.01-0.20 |
7 |
12 |
| pN1, LNR 0.21-0.65 |
4 |
1 |
| pN1, LNR > 0.65 |
0 |
0 |
| Estrogen receptor positive |
28 |
27 |
| Progesterone receptor positive |
21 |
25 |
| HER2 FISH amplified |
2 |
8 |
| Histological grade |
|
|
| 1 |
11 |
11 |
| 2 |
8 |
18 |
| 3 |
10 |
8 |
| unknown |
3 |
0 |
| Surgery |
|
|
| Breast conserving |
21 |
20 |
| Axillary lymph nodes |
|
|
| Sentinel biopsy only |
20 |
17 |
| Sentinel with axillary dissection |
4 |
6 |
| Immediate axillary dissection |
8 |
14 |
| Radio-chemotherapy schedule |
|
|
| No adjuvant chemotherapy |
18 |
17 |
| RT after completion of chemotherapy |
3 |
5 |
| RT concomitant with start chemotherapy |
11 |
15 |
| Chemotherapy type |
|
|
| Anthracycline without taxane |
3 |
4 |
| Anthracycline with taxane |
10 |
15 |
| CMF |
1 |
1 |
| Hormone therapy |
|
|
| No hormone therapy |
4 |
10 |
| Tamoxifen |
15 |
11 |
| Letrozole |
13 |
11 |
| Zoladex |
0 |
1 |
| Tamoxifen + Zoladex |
0 |
4 |
| Trastuzumab | 2 | 8 |